The reference site for Clinafloxacin

Clinafloxacin is still under clinical development and has not yet received approval from the FDA.

According to the comparative analysis, clinafloxacin is one of the most potent agents against S. pneumoniae. However, other studies have shown severe toxicity (i.e. sever phototoxicity and hypoglycaemia).

Please visit the official site of the FDA for further information.

Clinafloxacin is a fourth generation quinolone that belongs to the antibacterial fluoroquinolone group. It has broad-spectrum activity against gram-negative and gram-positive bacteria, aerobes and anaerobes.

Quinolones work by inhibiting the bacterial DNA gyrase or the topoisomerase IV enzyme, thereby inhibiting DNA replication and transcription. Quinolones can enter cells easily and therefore are often used to treat intracellular pathogens.

According to a comparative analysis, clinafloxacin is one of the most potent agents against S. pneumoniae. Furthermore, clinafloxacin has been studied primarily in hospitalized adults for the treatment of serious and potentially life-threatening infections, including nosocomial pneumonia, community-acquired pneumonia, febrile neutropenia, complicated intra-abdominal infections, complicated skin and soft tissue infections, endocarditis, and acute gynecologic infections.

However, some studies have shown severe toxicity (i.e. sever phototoxicity and hypoglycaemia).

Clinafloxacin is undergoing extensive clinical development and is currently not available on the market.

The exact uses for this medication have not been defined.

Clinical trials have been carried out using multi-dose administration, but the exact dosage of treatment has not been determined.

This information will be provided once clinafloxacin has received FDA approval and is made available on the market.

Clinafloxacin is still under clinical development, and is not currently available on the market.

Therefore no special precautions are required as this medication will only be administered under specific supervision in a hospital or in further clinical studies.

Clinafloxacin is currently not available on the market, and information regarding a missed dosage procedure is yet to be defined.

This information will be included once it has received FDA approval.

The exact side effects caused by this medication have not been concluded as various clinical studies are currently in development. Nevertheless, gastrointestinal effects were the most common adverse side effects found.

Further information will be provided shortly.

Indications regarding storage conditions for clinafloxacin will be defined once this medication has been approved and is available on the market.

The symptoms of an overdose using clinafloxacin are not known as this medication is currently undergoing clinical studies.

However, in the case of a suspected overdose when using any form of medication, you should call your local poison control center on 1-800-222-1222, or the emergency services on 911 if the person has collapsed or is not breathing.